- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05338749
Computer Cognitive Training for Post-acute COVID-19 Syndrome (PACS-Cog)
March 28, 2024 updated by: Nova Southeastern University
An Open-label Trial of Computer-delivered Cognitive Training in Persons With Post-acute COVID-19 Syndrome
This study will assess the acceptability, feasibility, and impact of game-based computer-delivered cognitive training on cognitive function in persons with cognitive symptoms that persist after recovery from acute coronavirus-19 (COVID) infection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Over the course of the past several years, it has become apparent that a number of individuals have residual symptoms after COVID-19 infection after they have recovered from the acute phase of the illness (Al-Aly, Xie, & Bowe, 2021; Davis et al., 2021; Greenhalgh, Knight, A'Court, Buxton, & Husain, 2020; Hewitt et al., 2021).
The constellation of symptoms experienced by these individuals has been termed "post-acute COVID syndrome" or PACS (Nalbandian et al., 2021).
A key part of helping affected individuals is supporting their efforts at self-management of these symptoms (National Institute for Health and Care Excellence, 2020; Wade, 2020).
Although a diverse number of physical and psychological symptoms have been seen as sequelae of COVID (Davis et al., 2021), among the most troubling for patients have been difficulties in attention, concentration, working memory, and long-term memory, commonly referred to as "brain fog" (Graham et al., 2021; Hampshire et al., 2021; Hewitt et al., 2021).
In the proposed study, we will complete a pilot study of game-based cognitive training in persons with symptoms of long COVID using a protocol that was useful and acceptable to participants in a previous study (Ownby & Kim, 2021).
We will explore participants' views on the cognitive training intervention, its effects on their perceived cognitive functioning, and assess the intervention's impact on participants' processing speed.
We will also explore their preferences for type of cognitive training activity and the impact of information about memory functioning.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33314
- Center for Collaborative Research, Nova Southeastern University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Persons with a history of COVID-19 infection confirmed through screening of symptom pattern or testing and report of mental symptoms (difficulties in attention, memory, or executive functions such as coordinating two activities at once) more than 30 days after resolution of the initial acute infection.
Exclusion Criteria:
- Cognitive or psychiatric conditions of a severity that precludes the person's ability to give informed consent for their participation or to attend and cooperate with assessment and training, as judged by the investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cognitive Training
Participants in this condition will received game-based cognitive training.
|
Gamified cognitive training intervention to improve mental speed and attention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Technology Acceptance Model Questionnaire, Usefulness subscale
Time Frame: Three weeks
|
User self-report of their perception that an application serves a function that may be helpful The score is the average of several items rated by the user from 0 to 6, so that the final score itself can range from 0 to 6. Higher scores indicate that the user found the intervention more useful.
Higher scores are better.
|
Three weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive Failures Questionnaire
Time Frame: Three weeks
|
A standard self-report measure of problems in memory, attention, and self-regulated behavior.
This measures includes self-report ratings on 25 items, with ratings ranging from 0 to 4. The total score can thus range from 0 to 100, with higher scores indicating that the person experiences more problems with thinking and remembering.
|
Three weeks
|
|
Trail Making Test, Part B
Time Frame: Three weeks
|
This is a measure of how rapidly a person can remember alternating sequences of numbers and letters while connecting them on a paper with a pencil.
The score is time in seconds to complete the task, with the provision that if a person cannot finish the task within three minutes, the task is discontinued and the person is assigned a score of 180 (for 3 minutes times 60 seconds).
Lower scores indicate better performance.
|
Three weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Raymond L Ownby, MD, PhD, Nova Southeastern University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2022
Primary Completion (Actual)
November 30, 2023
Study Completion (Actual)
November 30, 2023
Study Registration Dates
First Submitted
April 14, 2022
First Submitted That Met QC Criteria
April 19, 2022
First Posted (Actual)
April 21, 2022
Study Record Updates
Last Update Posted (Actual)
March 29, 2024
Last Update Submitted That Met QC Criteria
March 28, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Neurocognitive Disorders
- Disease Attributes
- Cognition Disorders
- Chronic Disease
- Post-Infectious Disorders
- COVID-19
- Coronavirus Infections
- Cognitive Dysfunction
- Post-Acute COVID-19 Syndrome
Other Study ID Numbers
- 20211020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data sharing plan
IPD Sharing Time Frame
After completion of study
IPD Sharing Access Criteria
On request from any qualified investigator.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Dysfunction
-
Maria PaçoEnrolling by invitationDietary Supplements | Cognitive Dysfunction, Cognitive DisorderPortugal
-
Universidad Autónoma del Estado de HidalgoEnrolling by invitationCognitive Dysfunction ( MMSE < 24 )Mexico
-
Mu Dong LiangNot yet recruitingPostoperative Cognitive Dysfunction(POCD)
-
Xijing HospitalFirst Affiliated Hospital Xi'an Jiaotong University; Shanghai 10th People's... and other collaboratorsTerminatedPost Operative Cognitive DysfunctionChina
-
Icahn School of Medicine at Mount SinaiNational Institute on Aging (NIA)CompletedPost Operative Cognitive DysfunctionUnited States
-
Loma Linda UniversityCompleted1. Postoperative Cognitive DysfunctionUnited States
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingPOCD - Postoperative Cognitive DysfunctionChina
-
HealthPartners InstituteCompletedPost Operative Cognitive DysfunctionUnited States
-
Burcu Ozalp HorsanaliCompletedPost Operative Cognitive Dysfunction
-
Minia UniversityRecruiting
Clinical Trials on Cognitive Training
-
Science and Research Centre KoperAlbert Einstein College of Medicine; University of Primorska; Vrije Universiteit...CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or FunctionSlovenia
-
Hospital de Clinicas de Porto AlegreYale UniversityUnknownAttention-deficit/Hyperactivity Disorder.Brazil
-
Universidade Federal do Rio de JaneiroUnknown
-
Chang Gung Memorial HospitalRecruitingVirtual Reality | Community-dwelling ElderlyTaiwan
-
Fanfan ZhengEnrolling by invitationDiabetes Mellitus, Type 2 | Aging | CognitionChina
-
Xuanwu Hospital, BeijingRecruitingMild Cognitive ImpairmentChina
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Chiang Mai UniversityCompletedMild Cognitive ImpairmentThailand
-
Chang Gung Memorial HospitalRecruitingMCI | SCD | Virtual RealityTaiwan
-
University of California, San FranciscoCompletedSchizophrenia | PsychosisUnited States